Is Bluejay Diagnostics, Inc. (BJDX) a Buy, Sell, or Hold?
NASDAQ : BJDX
Bluejay Diagnostics, Inc.
$1.45 USD
$0.15 (11.54%)
- Volume
- 1.44M
- Average Volume
- 4.01M
- Market Capitalization
- $657.63K
- P/E Ratio
- -0.09
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $16.68
- Year Low
- $1.03
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.81
| Source | Headline |
|---|---|
|
Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants globenewswire.com - 2026-06-05 20:13:00 |
|
What's Going On With Bluejay Diagnostics Shares On Wednesday?
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower on Wednesday. On Tuesday, the company disclosed a private placement that aims to raise up to $23.6 million. benzinga.com - 2026-06-03 11:48:19 |
|
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants globenewswire.com - 2026-06-02 12:19:00 |
|
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
ACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”) (NASDAQ: BJDX), a medical diagnostics company focused on near-patient testing for critical care, today announced a strategic partnership with Argonaut Manufacturing Services (“Argonaut”) to support the advancement of Bluejay's Symphony™ platform. globenewswire.com - 2026-06-02 06:30:00 |
|
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
ACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a corporate update highlighting progress achieved during the first quarter of 2026 and recent operational developments related to its Symphony™ near-patient diagnostic platform. globenewswire.com - 2026-05-07 16:01:00 |
|
Critical Contrast: Bluejay Diagnostics (NASDAQ:BJDX) & STERIS (NYSE:STE)
Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) and STERIS (NYSE: STE - Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent ratings defenseworld.net - 2026-04-27 02:22:53 |
